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Abstract 
Background: The taxonomy of cardiovascular (CV) diseases is divided into a broad spectrum 
of clinical entities. Many such diseases coincide in specific patient groups suggesting shared 
predisposition. 
Objectives: Focussing on coronary artery disease (CAD), we investigated the genetic 
relatedness to CV and non-CV diseases with reported CAD comorbidity. 
Methods: This study examined 425,196 UK Biobank participants to determine a genetic risk 
score (GRS) based on 300 CAD associated variants (CAD-GRS). This score was associated with 
22 traits, including risk factors, diseases secondary to CAD, as well as comorbid and non-CV 
conditions. Sensitivity analyses were performed in individuals free from CAD or stable angina 
diagnosis. 
Results: Hypercholesterolemia (odds ratio [OR]: 1.27; 95% CI: 1.26 to 1.29) and hypertension 
(OR: 1.11; 95% CI: 1.10 to1.12) were strongly associated with the CAD-GRS, which indicated 
that the score contained variants predisposing to these conditions. However, the CAD-GRS 
was also significant in patients with CAD who were free of CAD risk factors (OR: 1.37; 95% CI: 
1.30 to 1.44). The study observed significant associations between the CAD-GRS and 
peripheral arterial disease (OR: 1.28; 95% CI: 1.23 to 1.32), abdominal aortic aneurysms (OR: 
1.28; 95% CI: 1.20 to 1.37), and stroke (OR: 1.08; 95% CI: 1.05 to 1.10), which remained 
significant in sensitivity analyses that suggested shared genetic predisposition. The score was 
also associated with heart failure (OR: 1.25; 95% CI: 1.22 to 1.29), atrial fibrillation (OR: 1.08; 
95% CI: 1.05 to1.10), and premature death (OR: 1.04; 95% CI: 1.02 to 1.06). These associations 
were abolished in sensitivity analyses that indicated that they were secondary to prevalent 
CAD. Finally, an inverse association was observed between the score and migraine headaches 
(OR: 0.94; 95% CI: 0.93 to 0.96). 
Conclusions: A wide spectrum of CV conditions, including premature death, might develop 
consecutively or in parallel with CAD for the same genetic roots. In conditions like heart 
failure, the study found evidence that the CAD-GRS could be used to stratify patients with no 
or limited genetic overlap with CAD risk. Increased genetic predisposition to CAD was 
inversely associated with migraine headaches. 
 Condensed Abstract: Focussing on coronary artery disease (CAD), we investigated the genetic 
relatedness to cardiovascular and non-cardiovascular diseases in 425,196 UK Biobank 
participants. We determined a genetic risk score based on 300 CAD associated variants. 
Sensitivity analyses were performed in individuals free from a CAD or stable angina diagnosis. 
We found that genetic predisposition to CAD is associated with increased risk of other 
atherogenic diseases, while for conditions like heart failure our findings indicated that a large 
proportion of clinically appearing disease manifestations are secondary to CAD. Finally, the 
observed genetic overlap between CAD and migraine is driven by genetic loci with opposing 
effects. 
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Abbreviation list 
CAD = coronary artery disease 
GRS = genetic risk score 
CV = cardiovascular  
HES = Hospital Episode Statistics  
GWAS = genome-wide association study 
SNV = single nucleotide variant 
OR = odds ratio 
SD = standard deviation 
CI = confidence interval  
FDR = False discovery rate 
 
  
INTRODUCTION 
It is clinically evident that coronary artery disease (CAD) and a broad spectrum of other 
cardiovascular (CV) conditions often coincide in a given patient. CAD is caused by a number 
of factors that may also precipitate atherosclerosis in other vascular beds, leading to ischemic 
stroke, abdominal aortic aneurysms (1), peripheral arterial disease (2), or aortic stenosis (3). 
In contrast, CAD and its main complication, myocardial infarction (MI), increase the risk for 
developing conditions such as congestive heart failure (4), atrial fibrillation (5), or sudden 
cardiac death (6). It is currently unclear to which extent the genetic roots of CAD and these 
conditions overlap and contribute to the coincidence of CV diseases. 
Through large-scale, genome-wide association studies and targeted approaches (e.g., 
exome array) we and others have identified >243 CAD risk loci (7–12). Several of these known 
CAD risk loci have also been associated with other CV diseases (12). For example, the 
strongest association signal for CAD located at the 9p21 locus (11) has also been associated 
with carotid atherosclerosis (13), stroke (14), aneurysms (15), congestive heart failure (16), 
and CV mortality (17).  
The cumulative effect of CAD risk loci can be best depicted by a genetic risk score 
(GRS), which integrates the number and effect sizes of all known risk alleles of any given 
individual, which allows an aggregated and continuous quantitative measure of genetic 
susceptibility. Such GRSs may be better suited than single risk alleles to investigate the full 
genetic overlap between CAD and other heart and vascular diseases (18, 19). Tragante et al. 
(20) showed that a GRS based on 30 CAD risk variants was associated with peripheral arterial 
disease and ischemic stroke. However, due to the lack of comprehensively characterized and 
genotyped cohorts, there is limited information on how such a CAD-GRS relates to the full 
spectrum of CV diseases. 
UK Biobank is a large longitudinal biobank study in the United Kingdom (21). In 
addition to self-reported disease outcomes and extensive health and lifestyle questionnaire 
data, UK Biobank participants are being tracked through their National Health Service records 
and national registries. In 2017, UK Biobank released the genotypes of 488,377 participants, 
in whom we assessed the overlap in genetic risk between CAD and 13 CV disease phenotypes, 
mainly vascular, using CAD-GRS. We aggregated risk alleles of all CAD associated variants 
(genome-wide significant and a 5% false discovery rate). In addition, we tested the overlap of 
this score with traditional CAD risk factors, as well as 3 nonvascular diseases with some 
previous evidence of shared genetic predisposition to CAD, namely, renal disease (which is 
often associated with CV complications) (22), migraine headaches (23), and rheumatoid 
arthritis (24). 
 
METHODS 
STUDY POPULATION  
The UK Biobank project is a large prospective cohort study of approximately 500,000 
individuals aged 40 to 69 years at recruitment (21). Following informed consent, a rich variety 
of phenotypic and health-related information was collected for each participant. Biochemical 
data for each of the 4 main blood lipids were not avail-able at the time of analyses. Health-
related outcome records included death notifications and cancer diagnoses through linkage 
to national death and cancer registries, and hospital inpatient episode statistics, which 
contained coded data on admissions, operations, and procedures (primary and secondary).  
 
GENOTYPING QUALITY CONTROL 
Using sample quality control information provided by UK Biobank, we excluded 968 
heterozygosity and/or missingness outliers, 373 individuals with sex discordance, 471 
individuals with putative sex chromosome aneuploidy, and individuals who withdrew from 
the study, which resulted in 486,553 individuals (25). We restricted analyses to individuals of 
European ancestry by combining self-reported ethnicity and principal components (PCs) 
provided by UK Biobank. We used the kmeans algorithm in R 3.4.0 (R Foundation, Vienna, 
Austria) to perform a 4-means clustering for each of the first 5 PCs separately corresponding 
to 4 ethnic groups (white, black, Asian, Chinese). An intersection of these 2 clusterings 
resulted in 5 PC-derived clusters (white, black, Asian, Chinese, mixed/other). After 
intersecting self-reported ethnicity information with the derived PC ancestry clusters, we 
identified 460,312 Europeans. Related individuals were excluded from analyses (second 
degree of relationship or closer; kinship coefficient <0.088), which left 425,196 individuals 
with nonmissing data for most of the outcomes. When possible, we prioritized exclusion of 
control subjects for all investigated traits. 
 
DEFINITION OF CAD AND OTHER HEART AND VASCULAR DISEASES 
Hospital Episode Statistics (HES) data incorporates National Health Service data, 
clinical commissioning groups, and local area teams in the United Kingdom from 1997 to 
March 2015, with the Scottish data dating back as early as 1981. HES uses International 
Classification of Diseases-9 and -10to record diagnosis information, and Office of Population, 
Censuses and Surveys: Classification of Interventions and Procedures (version 4) to code 
operative procedures. Death registries include all deaths in the United Kingdom up to January 
2016, with both primary and secondary causes of death coded in International Classification 
of Diseases-10.Only participants admitted to the hospital had a HES record. To define disease 
cases, we leveraged all available data sources, i.e., self-reported data from baseline and 
follow-up assessments for diseases and operations, HES records, and death registry data 
(Online Table 1). As cases, we defined all individuals who had a prevalent outcome or 
developed the outcome in the observational period. Control subjects for each disease were 
defined as individuals who were not disease cases. Based on clinical reasoning, we divided 
the investigated traits relative to CAD in to underlying risk factors, comorbid conditions, 
conditions secondary to CAD, and diseases that did not primarily affect the heart and 
vasculature.  
 
CONSTRUCTION OF THE CAD-GRS 
The set of genome-wide significant single nucleotide variants for CAD (N=164) was 
expanded by including uncorrelated variants at a false discovery rate of 5% (7-12). For the 
SLC22A3/LPAL2/LPA/PLG and COL4A1/COL4A2 loci, we performed conditional analysis in the 
CARDIoGRAMplusC4D data (10) with GCTA software (26), and selected 7 and 4 conditionally 
independent variants, respectively. In estimating the additive effects of all variants, we did 
not include the 2 known recessive loci (rs11830157, KSR2; rs12976411, ZNF507-LOC400684). 
We included 319 variants (249 CAD loci), 282 of which were available in UK Biobank; 18had a 
proxy (r2>0.8), and 19 were not available. In total, we extracted 300 variants representing 
240 loci (Online Table 2).  
With these 300 variants, we calculated a weighted GRS (CAD-GRS) for all individuals. 
A value ranging from 0 to 2 was given to each individual for every variant according to the 
sum of the posterior probabilities of the imputed genotypes to indicate the number of CAD 
increasing alleles. We multiplied the number of risk alleles by their reported CAD effect sizes 
in Nelson et al. (12). Per individual, we totalled these values across all 300 variants to generate 
a weighted CAD-GRS, which we modeled as a continuous variable and standardized into Z-
scores (centered and scaled to have a mean of 0 and standard deviation [SD] of 1). We then 
calculated 5 quantiles of the standardized CAD-GRS and categorized individuals into 3 groups: 
Q1; Qreference (individuals from Q2 to 4), which served as the reference group; and Q5.  
 
GRS ASSOCIATION ANALYSES 
Logistic regression models implemented in R 3.4.0 (R Foundation) we reused to 
determine the association between CAD-GRS and other conditions. All phenotypes were 
coded as 0 (control subjects) or 1 (cases). All analyses were adjusted for age, sex, first 5 PCs, 
and genotyping array (UK Biobank vs.UK-BiLEVE). Regression coefficients of the CAD-GRS on 
each trait were calculated for an increase of 1 SD in the score and were converted to odds 
ratios (ORs). Sensitivity analyses were performed to investigate the effect of the CAD-GRS on 
trait prevalence, including CAD risk factors, comorbid conditions, diseases secondary to CAD, 
and non-CV diseases, in individuals free from CAD and/or angina diagnosis (n=389,952). We 
also performed sex-stratified analyses. Statistical significance was set to p<0.002 to account 
for the number of traits tested (a <0.05 divided by 23 traits). 
 
POWER CALCULATIONS 
We performed power calculations with QUANTO (27), assuming an average genetic 
frequency of 0.45 (mean frequency of all effect alleles included in the CAD-GRS), and trait 
prevalence was calculated as number of cases/(number of cases + number or control 
subjects). We had sufficient statistical power (>80%) for all out-comes, except for congenital 
heart disease, cardiomyopathy, pulmonary embolism, pericardial problem, sudden cardiac 
death, and vein thrombosis (Online Table 3). 
 
RESULTS 
We studied 425,196 unrelated UK Biobank participants of European ancestry, 21,051 
of whom had CAD (Table 1). The prevalence of all tested CAD risk factors and comorbid 
conditions is shown in Online Table 4. As expected, CAD risk factors and other CV diseases 
were significantly more prevalent among CAD cases compared with CAD-free individuals 
(p<0.05). We selected 300 previously published uncorrelated CAD associated variants (Online 
Table 2) to construct a CAD-GRS score.  
 
CAD-GRS AND CAD 
We first confirmed that the CAD-GRS was robustly associated with CAD prevalence 
(OR: 1.65 per 1 SD of the CAD-GRS; 95% confidence interval [CI]: 1.62 to 1.65) (Table 2, Figure 
1). CAD prevalence in the top quantile (Q5) of the CAD-GRS compared with the reference 
group (Qreference) was significantly higher (OR: 2.05; 95% CI: 1.99 to 2.12), whereas CAD 
prevalence in the lowest quantile (Q1) was significantly lower (OR: 0.53; 95% CI: 0.51 to 0.56) 
(Central Illustration). We then estimated the effect of the score on CAD prevalence after 
exclusion of all CAD cases with a known CAD risk factor (including hypercholesterolemia, 
hypertension, type 2 diabetes, and obesity). Despite the lower number of analysed CAD cases 
(n=1,543), the effect of the score on CAD prevalence remained significant (OR: 1.37; 95% CI: 
1.30 to 1.44). Although it was possible that some risk factor cases (e.g., patients with CAD 
with hyperlipidemia) were unreported, and serum lipid levels were unavailable at the time of 
analysis to corroborate findings, our results supported the wider view that the current set of 
known CAD variants captured more biological pathways than those corresponding to 
traditional risk factors. Exclusion of CAD cases with comorbid conditions (OR: 1.65; 95% CI: 
1.63 to 1.68 in the remaining 17,602 CAD cases) or exclusion of CAD cases with diseases 
secondary to CAD (OR: 1.67; 95% CI: 1.64 to1.70 in the remaining 13,533 CAD cases) did not 
significantly affect the association between the score and CAD prevalence.  
 CAD-GRS AND CAD RISK FACTORS 
We observed highly significant associations of the CAD-GRS with CAD risk factors 
(Table 2 and Figure 1). Repeating the preceding analyses after exclusion of all individuals with 
CAD and/or chronic angina (n=35,199) (Figure 2, Online Table 5) further demonstrated the 
robustness of the CAD-GRS association with hypercholesterolemia (OR: 1.04; 95% CI: 1.03 to 
1.06) and hypertension (OR: 1.04; 95% CI: 1.03 to 1.06). The signal observed for type 2 
diabetes was attenuated in the sensitivity analyses, but remained significant (OR: 1.04; 95% 
CI: 1.03 to 1.06). The lack of any effect of the score on smoking status after exclusion of CAD 
cases (OR: 1.00; 95% CI: 0.99 to 1.00) supported the view that it was mediated via the 
exposure, rather than by shared genetic underpinnings (Online Table 5). 
 
CAD-GRS AND COMORBID CONDITIONS 
We next investigated the extent to which there was a shared genetic component with 
other heart and vascular diseases. We observed significant associations (Table 2) between 
CAD-GRS and peripheral arterial disease (OR: 1.28; 95% CI: 1.23 to 1.32), abdominal aortic 
aneurysms (OR: 1.28; 95% CI: 1.20 to 1.37), aortic stenosis (OR: 1.21; 95% CI: 1.15 to 1.26), 
and stroke (OR: 1.08; 95% CI: 1.05 to 1.10). Although all these associations, apart from aortic 
stenosis, were attenuated in sensitivity analyses, they remained significant (Figure 2, Online 
Table 5). Stratification in disease prevalence was observed across CAD-GRS quantiles. In 
individuals in Q5, peripheral arterial disease was significantly more prevalent (OR: 1.35; 95% 
CI: 1.25 to 1.46) compared with Qreference, whereas prevalence in individuals in Q1 was 
significantly lower compared with Qreference (OR: 0.71; 95% CI: 0.64 to 0.79) (Central 
Illustration, Online Table 6). Although the same trend was observed in sensitivity analyses, 
the test did not reach our significance threshold, probably due to the smaller sample size (the 
coincidence of CAD and peripheral arterial disease was high) and a reduction in power (Online 
Table 3). Similar association trends were observed for abdominal aortic aneurysms and stroke 
(Central Illustration, Online Table 6). 
 
CAD-GRS AND DISEASES SECONDARY TO CAD 
The most significant association of the CAD-GRS was with heart failure (OR: 1.25; 95% 
CI: 1.22 to 1.29) (Table 2). However, after exclusion of CAD and/or stable angina cases from 
the analysis, the association was no longer significant (OR: 1.02; 95% CI: 0.97 to 1.07) (Figure 
1, Online Table 5). The lack of any signal for heart failure in the sensitivity analysis might 
suggest that the risk for heart failure among individuals with a high CAD-GRS was best 
explained by patients with prevalent CAD. Furthermore, there was a sizable subgroup of 
patients who developed heart failure with no or a limited overlap with CAD genetic risk 
factors. Atrial fibrillation and premature death gave similar results for heart failure because 
the strong association observed in the main analysis was statistically nonsignificant after 
exclusion of CAD cases (Figure 2, Online Table 5). After Bonferroni correction (a=0.05 divided 
by 23 traits), no significant associations were found for congenital heart disease, 
cardiomyopathy, pulmonary embolism, pericardial problems, sudden cardiac death, and vein 
thrombosis (Table 2), which might be due to insufficient statistical power (<80%) (Online 
Table 3). 
 
CAD-GRS AND NON-CV CONDITIONS 
We next tested the CAD-GRS for association with diseases that are not primarily 
related to heart and vasculature but postulated to have a shared genetic component with 
CAD, including migraine headaches, rheumatoid arthritis, and renal disease. Prevalence of 
migraine headaches was lower among CAD cases compared with control subjects (2.7% 
vs.3.5%) (Online Table 4). Likewise, a higher CAD-GRS was associated with a lower prevalence 
of migraine (OR: 0.94; 95% CI: 0.93 to 0.96) (Table 2), and this signal was not attenuated in 
sensitivity analysis (OR: 0.94; 95% CI: 0.93 to 0.96) (Figure 2, Online Table 5). Prevalence of 
migraine headaches was significantly lower in individuals in the highest CAD-GRS quantile 
compared with the reference group (OR: 0.90; 95% CI: 0.87 to 0.95) (Central Illustration, 
Online Table 6), and this association was only slightly attenuated but remained significant in 
sensitivity analyses. Three CAD loci (LRP1, PHACTR1, FHL5) reached genome-wide significance 
(p<5×10-8), and another 11 loci were associated with migraine headaches at p<10-3 (Online 
Table 7). After removal of the top variants in these loci from the CAD-GRS, we observed an 
attenuation in the association signal that nonetheless remained significant (Online Table 8). 
This indicated that the inverse association was based on a wide spectrum of genetic loci 
represented by the score.  
We observed that increased genetic predisposition for CAD, as indicated by the CAD-
GRS, was associated with an increased prevalence of rheumatoid arthritis (OR: 1.54; 95% CI: 
1.03 to 1.08) (Table 2); however, this did not remain significant in the sensitivity analysis 
(Figure 2, Online Table 5).  
The positive association observed between the score and either acute renal disease 
(OR: 1.06; 95% CI: 1.03 to 1.09) or chronic renal disease (OR: 1.06; 95% CI: 1.03 to 1.09) (Table 
2) did not remain significant in the sensitivity analysis (Figure 2, Online Table 5).  
The results of the sex-stratified analyses for all risk factors and disease phenotypes are 
summarized in Online Table 9. We did not observe any major sex differences for the CAD-GRS 
in the tested outcomes in the sensitivity analysis, except for peripheral arterial disease (males: 
OR: 1.17; 95% CI: 1.10 to 1.26; females: OR: 1.05; 95% CI: 0.98 to 1.13). 
 
DISCUSSION 
In this study, we made 3 principal observations. First, we demonstrated that genetic 
variants that affected CAD also contributed to the development of other diseases brought 
about by atherosclerosis (e.g., peripheral arterial disease), which suggested a shared inherited 
component. Second, in a large population sample such as UK Biobank, highly significant 
association signals of the CAD-GRS were observed in individuals with congestive heart failure, 
atrial fibrillation, and those who experienced premature death. These findings underscored 
an etiological role of genetics and the (often) preceeding manifestation of coronary disease 
in the development of these conditions. Third, the CAD-GRS was inversely associated with 
migraine and this signal was driven by a broad range of genetic variants with opposing effects 
on the 2 diseases.  
As expected, CAD-GRS was significant for all traditional CAD risk factors, but not for 
smoking, in which the effect was exerted through exposure. However, the significant 
association of CAD-GRS with CAD in individuals free of traditional risk factors suggested that 
there might be clinical usefulness in such a genetic score to identify people who are at risk, 
despite being free of known predisposing conditions.  
Applying a comprehensive CAD-GRS to >400,000 individuals revealed extensive 
sharing of genetic risk between CAD and multiple CV diseases. Because many such diseases 
are triggered by the same etiological substrate, an atherosclerotic lesion, this is not a surprise. 
It is conceivable that variants within the CAD-GRS that affect mechanisms that increase 
susceptibility to atherosclerosis might lead to manifestation of 1 or the other vascular bed, or 
their joint appearance (18, 28). This was shown specifically for the 9p21 locus, which had the 
strongest effect among common variants of CAD and/or MI risk because it was also associated 
with large artery stroke, abdominal aneurysms, and peripheral arterial disease (13–15). 
Looking at UK Biobank alone, the risk variant at the 9p21 locus reached genome-wide 
significance for abdominal aneurysms and peripheral arterial disease, but not with stroke. The 
CAD-GRS was significantly associated with prevalence of abdominal aneurysms, peripheral 
arterial disease, and stroke, which suggested a broader shared genetic component.  
Aortic stenosis, a manifestation of atherosclerosis in most patients, was also 
associated with CAD-GRS. However, the signal became insignificant when patients with 
known CAD or angina were excluded from the analyses. Beside the reduced statistical power 
in the sensitivity analysis (64% of aortic stenosis cases were excluded due to comorbid CAD 
or angina), the lack of association might be due to the fact that patients with severe aortic 
stenosis often underwent coronary angiography, which leads to a high sensitivity for 
diagnosing CAD. Helgadottir et al. (29) also reported that a weighted CAD-GRS based on 71 
CAD-associated variants was associated with aortic stenosis in an Icelandic population and 
individuals from UK Biobank, but this association did not remain significant after controlling 
for CAD diagnosis, which agreed with our results.  
The effect of the CAD-GRS on abdominal aneurysm, aortic stenosis, and peripheral 
arterial disease was 73% to 78% of the effect observed for CAD, whereas for stroke, it was 
65%. Thus, the observed attenuation in the association signals for the CAD-GRS implied some 
heterogeneity in the genetic component across these diseases. The effect of the CAD-GRS on 
CAD after exclusion of all comorbid conditions or diseases secondary to CAD suggested that 
some of the CAD risk alleles might be specific for CAD.  
The most significant association of the CAD-GRS with any of the other CV 
comorbidities was observed for congestive heart failure. This agreed with the clinical 
observation that ischemic heart disease is often accompanied by heart failure (30). MI is a 
well-established risk factor of heart failure (31). This association was no longer significant in 
the sensitivity analysis. In conjunction with the strength of the association between the CAD-
GRS and heart failure, this observation might also suggest that a large proportion of clinically 
appearing manifestations of heart failure were secondary or functionally related to CAD. 
Moreover, from a genetic point of view, it could be concluded that heart failure pathogenesis 
could be stratified based on CAD genetic risk, as well as other different mechanisms. It is 
clinically evident that multiple causes of heart failure coexist in a patient population with this 
syndrome (32).  
The significant association of CAD-GRS with premature death was not only clinically 
relevant, but was also a measure for the relevance of the genetic markers that constitute the 
CAD-GRS. The studies that led to identification of the CAD risk alleles used here were largely 
based on clinically identified patients (i.e., survivors of a MI) (11). This led to the criticism that 
these alleles might indicate markers for survival rather than disease. The observation that the 
CAD-GRS was related to worse outcome in the UK Biobank might dispute this line of thought 
and was in agreement with smaller studies on the topic (33, 34).  
Single variant and pathway analysis implicated genes involved in inflammation in both 
CAD and inflammatory conditions, such as rheumatoid arthritis (12). Likewise, clinical studies 
reported increased risk of CAD among rheumatoid arthritis patients (35), although results at 
the molecular level were not conclusive (24). In our analysis, CAD-GRS was significantly 
associated with rheumatoid arthritis, but this association did not remain significant in the 
sensitivity analysis.  
Finally, we observed a strong negative association between the CAD-GRS and migraine 
headaches, that is, an increased genetic predisposition to CAD was related to a lower 
prevalence of migraine headaches. Our results were in agreement with findings from another 
study that also indicated that a CAD poly-genic risk score was associated with a reduced risk 
of migraine (23). Specifically, it was shown that a CAD risk score was associated only with a 
reduced risk of migraine without aura, whereas no association was observed for the risk of 
migraine with aura; this indicated that the signal was mainly driven by a limited number of 
loci (23). Unfortunately, migraine was not defined in such detail in UK Biobank participants, 
and we were able to define only 29 and 194 patients without and with aura, respectively, 
using HES records. Three CAD-associated loci, LRP1, PHACTR1, and FHL5, are also known 
migraine risk loci (23, 36). In our study, the inverse association be-tween CAD-GRS and 
migraine could not be explained exclusively by variants in these loci and another 11 CAD loci 
that gave an inverse signal for migraine at p<10-3 in UK Biobank. This might indicate that 
there is a rather broad opposing genetic component be-tween CAD and migraine beyond the 
established loci. This might furthermore suggest that the related mechanisms influence 
crucially and delicately balanced traits in vascular biology in an opposing fashion. In the light 
of such inverse and apparently pleiotropic effects, it might be important to mention that the 
PHACTR1 risk allele also affects other vascular phenotypes, including fibromuscular dysplasia 
and arterial dissections in the opposite direction to CAD risk (37). 
 
STUDY LIMITATIONS 
First, despite the large sample size of UK Biobank, our study was underpowered for 
adequately studying a number of CV disease phenotypes, such as sudden cardiac death 
(n=198) or congenital heart disease (n=671). This was in part due to low prevalence, but 
underreporting might have contributed as well. The latter was exemplified by familial 
hypercholesterolemia, which was documented in only 50 patients, whereas approximately 
2,000 would have been expected because of the prevalence of respective mutations. The 
same applies to biochemical measures, like the lipid profile, that were not available for 
inclusion in our analyses. Another limitation might be seen in the precision of the diagnoses 
reported to the UK Biobank. For example, we could not differentiate between heart failure 
with reduced or preserved ejection fraction. Additionally, to increase our power, we 
estimated the effects of the CAD-GRS on overall disease prevalence, which did not allow us 
to distinguish any differences in the effects of the score between prevalent and incident 
disease cases. Furthermore, our CAD-GRS did not include all the variants that underlaid CAD 
risk. Recently, Khera et al. (38) showed that a polygenic risk score of 6.6 million common 
variants demonstrated the best predictive ability compared with scores derived by the 
aggregation of smaller number of variants. In addition, it was shown that the predictive 
capacity of genetic risk scores would be likely to improve further with the identification of 
more associated variants and more precise report of their effect sizes from larger genome-
wide association studies (39). Our study provided evidence of association between CAD-GRS 
and disease prevalence, but further studies are required to show whether this relationship is 
causal. The associations were obtained by studying individuals of mainly European descent 
(7–12), and disease prevalence in individuals of European ancestry in UK Biobank. Therefore, 
generalizability of our findings in other ancestral groups and their clinical usefulness remains 
to be tested. 
 
CONCLUSIONS  
Our results suggested that genetic predisposition to CAD also affected the prevalence 
of other CV diseases, including premature death. Genetic variants associated with increased 
risk of CAD were also associated with increased risk of other atherogenic diseases, whereas 
for conditions like heart failure, our findings indicated that a large proportion of clinically 
appearing manifestations of the disease were secondary to CAD. Finally, the genetic overlap 
between CAD and migraine was based on a range of genetic loci with opposing effects to the 
2 diseases. 
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PERSPECTIVES 
COMPETENCY IN MEDICAL KNOWLEDGE: Genetic factors related to risk of coronary disease 
are associated with multiple CV conditions and premature death.  
TRANSLATIONAL OUTLOOK: Further studies are needed to elucidate the mechanisms that link 
genetic variants associated with coronary risk and how they contribute to the risk of 
developing other diseases as well. 
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Table 1 Characteristics of all UK Biobank participants and of selected disease cases. 
  N 
Age, years  
(Mean ± standard 
deviation) 
Sex  
(Male, %) 
All individuals  425,196 56.65 ± 8.00 45.86 
Coronary artery disease (CAD) cases  21,051 61.62 ± 8.28 68.10 
CAD and/or stable angina cases  35,199 61.46 ± 6.17 21.82 
Cases of CAD risk factors     
   Hypercholesterolemia  79,552 61.17 ± 6.13 60.51 
   Hypertension  209,513 59.17 ± 7.15 53.16 
   Obesity (BMI ≥ 30kg/m2) 101,403 57.04 ± 7.74 48.49 
   Ever smokers 138,236 57.63 ± 7.78 53.76 
   Type 2 diabetes  19,274 60.51 ± 6.62 62.69 
Cases of comorbid conditions with CAD     
   Abdominal aortic aneurysm  949 64.5 ± 4.17 87.98 
   Aortic stenosis  1,799 62.58 ± 5.78 65.31 
   Peripheral arterial disease  3,305 61.02 ± 6.74 65.35 
   Stroke  9,664 59.6 ± 6.72 59.06 
Cases of diseases secondary to CAD       
   Atrial fibrillation  15,319 62.17 ± 5.86 67.72 
   Congenital heart disease  671 56.16 ± 7.99 47.39 
   Cardiomyopathy  1,457 59.6 ± 7.01 67.74 
   Heart failure  5,735 62.03 ± 6.06 70.98 
   Pulmonary embolism  6,068 59.52 ± 7.18 50.52 
   Pericardial problem  1,561 59.42 ± 7.27 65.59 
   Premature death  11,110 61.14 ± 6.32 61.19 
   Sudden cardiac death  198 61.09 ± 6.5 69.69 
   Vein thrombosis  10,561 59.6 ± 7.12 44.54 
Cases of non-cardiovascular conditions     
   Migraine  14,718 55.47 ± 7.7 23.52 
   Rheumatoid arthritis   6,808 59.43 ± 7 32.87 
   Acute renal disease  4,591 61.38 ± 6.43 64.95 
   Chronic renal disease  5,393 61.86 ± 6.32 57.92 
 
  
Table 2 Effect of the genetic risk score for coronary artery disease (CAD-GRS) on CAD 
prevalence and prevalence of selected diseases. 
  All individuals  
  Prevalence (%) OR 95% CI 
Coronary artery disease (CAD) 5.1 1.65 1.65-1.62 
CAD risk factors     
   Hypercholesterolemia 18.7 1.27 1.26-1.29 
   Hypertension 49.3 1.11 1.10-1.11 
   Obesity 23.8 1.02 1.02-1.03 
   Smoking (ever vs never smokers) 37.7 1.01 1.01-1.02 
   Type 2 diabetes 4.5 1.11 1.09-1.13 
Comorbid conditions with CAD       
   Abdominal aortic aneurysm 0.2 1.28 1.20-1.37 
   Aortic stenosis 0.4 1.21 1.15-1.26 
   Peripheral arterial disease 0.8 1.28 1.23-1.32 
   Stroke 2.3 1.075 1.05-1.10 
Diseases secondary to CAD    
   Atrial fibrillation 3.6  1.07 1.05-1.08 
   Congenital heart disease 0.2 1.03 0.95-1.11 
   Cardiomyopathy 0.3 1.03 0.97-1.08 
   Heart failure 1.3 1.25 1.22-1.29 
   Pulmonary embolism 1.4 1.01 0.99-1.04 
   Pericardial problem 2.6 1.07 1.02-1.13 
   Premature death 2.6 1.04 1.02-1.06 
   Sudden cardiac death 0.05 1.18 1.02-1.35 
   Vein thrombosis 2.5 1.02 1.00-1.04 
Non-cardiovascular conditions    
   Migraine 3.5 0.94 0.93-0.96 
   Rheumatoid arthritis  1.6 1.05 1.03-1.08 
   Acute renal disease 1.1 1.06 1.03-1.09 
  All individuals  
  Prevalence (%) OR 95% CI 
   Chronic renal disease 1.3  1.06 1.03-1.09 
 
The genetic risk score was derived using the 300 SNPs associated with CAD, was standardized 
into Z-scores (centred and scaled to have a mean of 0 and standard deviation (SD) of 1), and 
modelled as a continuous variable. All estimates were derived in UK Biobank using logistic 
regression models (adjusting for age, sex, genotyping array and the first 5 principal 
components of ancestry). Odds ratios (OR) are reported for a one SD increase in the weighted 
genetic risk score of CAD. OR: odds ratio; CI: confidence interval. 
 
 
  
Figures 
Figure 1 Association of CAD-GRS with selected diseases 
Association of coronary artery disease genetic risk score (CAD-GRS), consisting of 300 CAD risk alleles, with traditional CAD risk factors, CAD 
comorbid conditions, and diseases secondary to CAD including premature death in the UK Biobank. All arrows indicate significant associations. 
* Association between the CAD-GRS and disease prevalence was no longer significant after exclusion of CAD and/or angina cases from the 
analyses. 
 
Figure 2 Sensitivity analysis of CAD-GRS effect on prevalence of selected traits 
Effect of the genetic risk score for coronary artery disease (CAD-GRS) on prevalence of 
selected traits in all individuals (dark blue) and in individuals without CAD and/or angina 
diagnosis (light blue). Odds ratios (ORs) are reported for a one SD increase in the weighted 
CAD-GRS. Lines show the 95% CI.  
 
Central Illustration Stratified analysis of coronary artery disease genetic risk score  
Bars show prevalence of disease within each group. The odds ratios (ORs) for individuals in 
Quintile 1 and Quintile 5 of the CAD-GRS were compared with these of individuals in the 
intermediate quantiles (Quintiles 2-4, reference). Results are presented only for diseases 
that passed the significance threshold. Detailed results are provided in Online Table 6. 
* Association did not reach our significance threshold. 
 
 
